Skip to content

Can weight loss surgery help improve sleep apnea and metabolic health? A long-term study of sleeve gastrectomy outcomes

Long-term effects of sleeve gastrectomy on metabolic parameters, and obstructive sleep apnea resolution: a prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN62397779
Enrollment
72
Registered
2025-07-10
Start date
2018-05-16
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long-term impact of metabolic and bariatric surgery, specifically sleeve gastrectomy, on obstructive sleep apnea and cardiometabolic disorders in patients with obesity: A five-year follow-up study. Nutritional, Metabolic, Endocrine

Interventions

This is a prospective observational cohort conducted by the Bariatric Medicine, Bariatric Surgery and the Pulmonary Medicine departments at Hamad Medical Corporation. Preoperatively, patients were a

Sponsors

Hamad Medical Corporation
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged between 18 to 60 years old 2. Eligible for metabolic and bariatric surgery, and selected the sleeve gastrectomy as their procedure 3. Agreed to participate in the research

Exclusion criteria

Exclusion criteria: 1. Previous bariatric procedure (e.g. gastric band, intragastric gastric balloon) 2. Current use of steroids 3. Uncontrolled psychiatric illness 4. Alcohol or substance abuse

Design outcomes

Primary

MeasureTime frame
The following outcome variables assess changes in anthropometric and cardiometabolic parameters at baseline and five years after the surgery, including: Types of medical comorbidities, type of and the number of medications and insulin therapy use, anthropometric parameters [e.g. weight, height, neck circumference (NC), waist circumference (WC)]. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also recorded. Laboratory tests included fasting blood glucose (FBS), hemoglobin A1c (HBA1C), insulin level, triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC). Postoperatively, at five years, all information was collected again, including blood tests, Stop Bang questionnaire and polysomnography parameters [apnea hypopnea index (AHI), oxygen desaturation index (ODI)]. The following outcome variables assess the remission/improvement of obesity-related comorbidities of type 2 diabetes mellitus, hypertension, and dyslipidemia before and after surgery: Blood test parameters and the number of medications used for each disease studied. For type 2 diabetes mellitus: HBA1C, fasting blood sugar, insulin use, number of medications used, for hypertension: blood pressure readings and the number of medications used, for dyslipidemia: lipid profile: total cholesterol, triglyceride, HDL, LDL, and the number of medications used.

Secondary

MeasureTime frame
Remission/ improvement /worsening of obstructive sleep apnea (OSA) measured using polysomnography and improved repeat score of AHI (Apnea Hypopnea Index) on the screening tool compared with preoperative. Decreased severity of disease on repeat objective testing with PSG: AHI < 5 (e.g., going from severe to mild or from mild to normal) before and after surgery.

Countries

Qatar

Contacts

Public ContactWahiba Elhag Elhag
WElhag1@hamad.qa+97433065586

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026